Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
AbbVie's Costly Apogee Acquisition Has Long-Term Upside: Analyst
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.read more...
Benzinga

Advertisement|Remove ads.